Moshe Oren

Weizmann Institute of Science — Israel

Medicine · Health Sciences

132h-index69.4kcitations506works12.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(264), Cancer Research and Treatments(97), Ubiquitin and proteasome pathways(62), RNA modifications and cancer(57), Epigenetics and DNA Methylation(51)

Publications503 total

p53 regulates the expression of histone modifiers to restrict stemness and maintain differentiated luminal identity in breast cancer
Proceedings of the National Academy of Sciences·2025Open Access
GLYATL1 is associated with metabolic and epigenetic changes and with endocrine resistance in luminal breast cancer
2025Open Access
The legacy of a gentleman scientist: Pierre Hainaut
Cell Death and Differentiation·2025Open Access
Sensitizing Immune-Refractory Ovarian Tumors via p53 Mutation-Tailored Immunotherapy
2025Open Access
Abstract LB457: Suppressing liver metastasis growth by inducing the endogenous expression of the tumor suppressor miR-34a by small synthetic molecules
Cancer Research·2025
The Role Of Tumour Suppressor Genes In Apoptosis
2024· 2 cited
Author Correction: ASS1 metabolically contributes to the nuclear and cytosolic p53-mediated DNA damage response
Nature Metabolism·2024· 3 citedOpen Access
Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer
Nature Medicine·2024· 41 citedOpen Access
ASS1 metabolically contributes to the nuclear and cytosolic p53-mediated DNA damage response
Nature Metabolism·2024· 24 citedOpen Access
ARTS and small-molecule ARTS mimetics upregulate p53 levels by promoting the degradation of XIAP
APOPTOSIS·2024· 5 citedOpen Access
ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC
Cell Death and Disease·2024· 10 citedOpen Access
Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability
Molecular Systems Biology·2024· 21 citedOpen Access
p53: A tale of complexity and context
Cell·2024· 55 citedOpen Access
p53 deficient breast cancer cells reprogram preadipocytes toward tumor-protective immunomodulatory cells
Proceedings of the National Academy of Sciences·2023· 10 citedOpen Access
ARTS and small-molecule ARTS mimetics upregulate p53 levels by promoting the degradation of XIAP
Research Square (Research Square)·2023Open Access
<scp>TAZ</scp> facilitates breast tumor growth by promoting an immune‐suppressive tumor microenvironment
Molecular Oncology·2023· 7 citedOpen Access
Deciphering the involvement of the Hippo pathway co-regulators, YAP/TAZ in invadopodia formation and matrix degradation
Cell Death and Disease·2023· 8 citedOpen Access
Supplementary Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023Open Access
Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023Open Access
Supplementary Figure from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023· 1 citedOpen Access
page 1 of 26Next →

Frequent Co-authors

Arnold J. Levine(7), Ruth Maya(5), Daniel Eliyahu(4), Tanya Gottlieb(4), Ygal Haupt(3), Adi Kimchi(3), Yaacov Barak(3), Sylvia Wilder(3), Dan Michalovitz(3), Dganit Shkedy(3), Yosef Shiloh(3), Karen H. Vousden(3), Elisheva Yonish-Rouach(2), T. Juven(2), Cathy A. Finlay(2), Philip W. Hinds(2), Tse‐Hua Tan(2), Varda Rotter(2), David Givol(2), O Pinhasi-Kimhi(2)